The Effect of Daily Low Dose Tadalafil on Cerebral Perfusion and Cognition in Patients with Erectile Dysfunction and Mild Cognitive Impairment-Reference-Cited by-同舟云学术

The Effect of Daily Low Dose Tadalafil on Cerebral Perfusion and Cognition in Patients with Erectile Dysfunction and Mild Cognitive Impairment

Published:2019-08-31 Issue:3 Volume:17 Page:432-437
ISSN:1738-1088
Container-title:Clinical Psychopharmacology and Neuroscience
language:en
Short-container-title:Clin Psychopharmacol Neurosci

Author:

Choi Jin Bong¹,Cho Kang Jun¹,Kim Joon Chul¹,Kim Chung Ho²,Chung Yong-An³,Jeong Hyeonseok S.³,Shim Yong Soo⁴,Koh Jun Sung¹^ORCID

Affiliation:

1. Departments of Urology College of Medicine, The Catholic University of Korea, Seoul, Korea

2. Departments of Nuclear Medicine The Catholic University of Korea, Seoul, Korea

3. Department of Radiology, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

4. Neurology, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

Publisher

Korean College of Neuropsychopharmacology

Subject

Pharmacology (medical),Behavioral Neuroscience,Psychiatry and Mental health

Link

http://pdf.medrang.co.kr/CPN2/2019/017/cpn017-03-11.pdf

Reference27 articles.

1. Phosphodiesterase type 5 (PDE5) inhibition improves object recognition memory: Indications for central and peripheral mechanisms

2. Resting cerebral blood flow, attention, and aging

3. Kurt M, Bilge SS, Aksoz E, Kukula O, Celik S, Kesim Y. Effect of sildenafil on anxiety in the plus-maze test in mice. Pol J Pharmacol 2004;56:353-357.

4. Neurologic, Psychological, and Aggressive Disturbances with Sildenafil

5. Selective phosphodiesterase inhibitors: a promising target for cognition enhancement

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phosphodiesterase Type 5 Inhibitors in Men With Erectile Dysfunction and the Risk of Alzheimer Disease;Neurology;2024-02-27

2. Polypharmacological Potential of Phosphodiesterase 5 Inhibitors for the Treatment of Neurocognitive Disorders;aging and disease;2024

3. A case-control study of phosphodiesterase-5 inhibitor use and Alzheimer’s disease and related dementias among male and female patients aged 65 years and older supporting the need for a phase III clinical trial;PLOS ONE;2023-10-18

4. Nitric oxide/cGMP/CREB pathway and amyloid-beta crosstalk: From physiology to Alzheimer's disease;Free Radical Biology and Medicine;2022-11

5. No association between initiation of phosphodiesterase-5 inhibitors and risk of incident Alzheimer’s disease and related dementia: results from the Drug Repurposing for Effective Alzheimer’s Medicines study;Brain Communications;2022-09-01